Brookfield Corp’s Ionis Pharmaceuticals IONS Stock Holding History

Brookfield Corp’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-9,638	Closed	-$293K	–	710
2021 Q4	$293K	Buy	+9,638	New	+$303K	﹤0.01%	582
2021 Q3	–	Sell	-13,568	Closed	-$541K	–	572
2021 Q2	$541K	Buy	+13,568	New	+$531K	﹤0.01%	502
2021 Q1	–	Sell	-18,513	Closed	-$1.05M	–	507
2020 Q4	$1.05M	Buy	+18,513	New	+$923K	﹤0.01%	365

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.32B AUM 32.9% 1-Year Est. Return

Brookfield Corp's IONS Position: Q1 2022 in Review

Brookfield Corp sold out of Ionis Pharmaceuticals (IONS) in Q1 2022, closing a stake of 9,638 shares — an estimated $293K sold.

Brookfield Corp first reported a position in IONS in Q4 2020 and held it in 3 quarters. The position peaked at $1.05M in Q4 2020. 334 funds tracked by Wall St. Rank hold IONS as of Q1 2022.

Brookfield Corp reported no remaining Ionis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Brookfield Corp sold 9,638 Ionis Pharmaceuticals shares in Q1 2022, an estimated $293K.
Brookfield Corp first reported a position in Ionis Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Brookfield Corp's Ionis Pharmaceuticals position peaked at $1.05M in Q4 2020.
334 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2022.

Based on Brookfield Corp's 13F filing for Q1 2022, filed 16 May 2022.